We don't know whether the most recent response to this request contains information or not – if you are BEN HOLDSWORTH please sign in and let everyone know.

Breast Cancer Treatment

We're waiting for BEN HOLDSWORTH to read recent responses and update the status.

Dear Whittington Health NHS Trust,

I would like to please request the following information with regards to Breast Cancer Treatment, on behalf of Novartis.

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
• Abemaciclib (Verzenios) + aromatase inhibitor *
• Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
• Alpelisib (Piqray) + Fulvestrant (Faslodex)
• Atezolizumab (Tecentriq)**
• Bevacizumab (Avastin)
• Eribulin (Halaven)
• Everolimus (Afinitor) + Exemestane
• Fulvestrant (Faslodex) as a single agent
• Gemcitabine + paclitaxel
• Herceptin (Trastuzumab) + paclitaxel
• Herceptin (Trastuzumab) as a single agent
• Lapatinib (Tyverb)
• Neratinib (Nerlynx)
• Olaparib (Lynparza)
• Palbociclib (Ibrance) + aromatase inhibitor*
• Palbociclib (Ibrance) + Fulvestrant (Faslodex)
• Pertuzumab (Perjeta) + trastuzumab + docetaxel
• Ribociclib (Kisqali) + aromatase inhibitor*
• Ribociclib (Kisqali) + Fulvestrant (Faslodex)
• Talazoparib (Talzenna)
• Trastuzumab emtansine (Kadcyla)
• Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent

Q2. For the above patients, how many of these received their first ever dose for each product line?

Sincerely thank you for taking the time to answer these questions.

Yours faithfully,
Ben Holdsworth

WHITTHEALTH, Foi (WHITTINGTON HEALTH NHS TRUST), Whittington Health NHS Trust

1 Attachment

FoI request re: Breast Cancer Treatment

Ref: 22-BH-2809

 

Dear Ben Holdsworth,

 

This is to acknowledge receipt of your request for information relating to
the number of patients treated for Breast cancer in the past 3 months.
This was received on 31 August 2022.

 

We can confirm that your request is being dealt with under the terms of
the Freedom of Information Act 2000 and that you can expect to receive a
reply within the timescale specified.

The timescale allowed for a response under the FOI legislation is 20
working days therefore, including any impending public holidays, the
deadline for a response is 28 September 2022. If we are able to respond to
you earlier than this, we will do so.

Your request has been forwarded to the relevant department and we'll get
back to you if there is any need for clarification.

 

Please quote the above reference in any further communication on this
matter.

 

Yours sincerely

 

FOI Coordinator

Freedom of Information Office

Whittington Health

Highgate Wing, Level 5

Magdala Avenue

London, N19 5NF

[1][Whittington Health NHS Trust request email]

 

 

show quoted sections

WHITTHEALTH, Foi (WHITTINGTON HEALTH NHS TRUST), Whittington Health NHS Trust

1 Attachment

FoI request re: Breast Cancer Treatment

Ref: 22-BH-2809

 

Dear Ben Holdsworth,

 

Thank you for your request for information relating to the number of
patients treated for Breast cancer in the past 3 months.

 

This was received on 31 August 2022 and has been dealt with under the
terms of the Freedom of Information Act 2000.

 

Please find our responses below:

Request 1:

In the past 3 months (or the latest 3 months data you have available), how
many Metastatic/advanced Breast cancer patients were treated with:

 

Abemaciclib (Verzenios) + aromatase inhibitor * 0
Abemaciclib (Verzenios) + Fulvestrant (Faslodex) ≤5
Alpelisib (Piqray) + Fulvestrant (Faslodex) 0
Atezolizumab (Tecentriq)** 0
Bevacizumab (Avastin) 0
Eribulin (Halaven) ≤5
Everolimus (Afinitor) + Exemestane 0
Fulvestrant (Faslodex) as a single agent 0
Gemcitabine + paclitaxel 0
Herceptin (Trastuzumab) + paclitaxel 0
Herceptin (Trastuzumab) as a single agent ≤5
Lapatinib (Tyverb) 0
Neratinib (Nerlynx) 0
Olaparib (Lynparza) ≤5
Palbociclib (Ibrance) + aromatase inhibitor* 7
Palbociclib (Ibrance) + Fulvestrant (Faslodex) ≤5
Pertuzumab (Perjeta) + trastuzumab + docetaxel 0
Ribociclib (Kisqali) + aromatase inhibitor* 0
Ribociclib (Kisqali) + Fulvestrant (Faslodex) 0
Talazoparib (Talzenna) 0
Trastuzumab emtansine (Kadcyla) 9
Other active systemic anti-cancer therapy ** 0

 

*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

**eg. docetaxel, vinorelbine or capecitabine as a single agent

Please note that the trust’s policy is not to provide patient or staff
numbers, where the response is less than or equal to five (≤5) as it would
potentially allow identification of the individual patient/staff and would
therefore be personal data. The trust considers that release of that
information would breach GDPR/DPA18 principles on the grounds that it
would not be fair in all the circumstances.  This information is therefore
exempt under section 40 of the FOI Act 2000.

 

Request 2:

For the above patients, how many of these received their first ever dose
for each product line?

≤5

 

I hope you find this information useful.  Please quote the above reference
in any further communication on this matter.

 

If you require any further assistance, please do not hesitate to contact
me by email or at the address shown below.

 

Yours sincerely

 

FOI Coordinator

 

Please note since 1^st August 2022, for cyber security reasons, we are no
longer able to open any email attachments, or click on links, contained
within FOI requests. The full details of the FOI request must be contained
within the main body of the email.

 

Freedom of Information Office

Whittington Health

Highgate Wing, Level 5

Magdala Avenue

London, N19 5NF

[1][Whittington Health NHS Trust request email]

 

 

If you are dissatisfied with this response, Whittington Health operates a
complaints procedure, details of which can be found below:
FOI Complaints: If you remain dissatisfied with the
Trust’s response, you may write to:
In the first instance, write to:
Information Commissioner's Office
Director Lead for Information
Governance Wycliffe House

Chief Operating Officer Water Lane

Jenner Building Wilmslow

Magdala Avenue Cheshire SK9 5AF

London Telephone: 0303 123 1113 or 01625
545745
N19 5NF
[3]www.ico.org.uk
020 7288 5255
 
[2][Whittington Health NHS Trust request email]

 

 

show quoted sections

We don't know whether the most recent response to this request contains information or not – if you are BEN HOLDSWORTH please sign in and let everyone know.